Restructure

More pink slips at AstraZeneca

By

Days after announcing a sharp downsizing, the patent expiry-plagued company said it will eliminate an additional 2,300 jobs, raising the tally of cuts to more than 5,000 through 2016.

Ex-Pfizer chief takes over at troubled Optimer

Ex-Pfizer chief takes over at troubled Optimer

By

Former Pfizer chieftain Hank McKinnell is taking the reins at stock scandal-plagued Optimer—perchance to sell it to Pfizer?

Novartis shakes up C-Suite as sales slide 3%

By

The latest executive change has a touch of deja-vu: Novartis vet Jorg Reinhardt is returning from a stint at Bayer.The company also said it expects 2013 sales to be flat, but sees growth in 2014 and 2015.

Endo rebrands to move beyond roots in pain drugs

Endo rebrands to move beyond roots in pain drugs

By

Endo is restructuring, bringing its four operating units under the same corporate roof and rebranding to reflect its diversification out of its origins in pain and urology drugs.

Sanofi braces for patent cliff impact

Sanofi braces for patent cliff impact

By

Sanofi is girding itself for an ugly year, forecasting a 12%-15% drop in business earnings per share for 2012 as the company absorbs the loss of patent exclusivity on a stable of drugs that brought in more than €4 billion last year.

Abbott to split off branded pharma unit, pursue specialty drug focus

By

Abbott said today it will separate into two publicly traded companies, one its $18-billion pharma unit and the other its $22-billion diversified medical products business.

Digitas Health, Razorfish Health to share new leadership, global team, in efficiency-driven reorg

Digitas Health, Razorfish Health to share new leadership, global team, in efficiency-driven reorg

By

Digitas Health and Razorfish Health are undergoing an organizational restructure in which the two Publicis-owned siblings will share two newly appointed co-presidents, launch a single global leadership team and develop a variety of centers of excellence.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters